UID:
edoccha_9960073358702883
Format:
1 online resource (xi, 190 pages) :
,
illustrations (some color)
ISBN:
0-12-397794-0
Series Statement:
Japan Annual Reviews in Electronics, Computers and Telecommunications
Content:
Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care provides an in-depth review of the state of translational science across all stages of pharmaceutical development with a special focus on personalized health care. This book provides a complete picture of biomarker development and validation in a pharmaceutical setting while addressing the inherent challenges of targeting the appropriate indications, biomarker robustness, regulatory hurdles, commercialization and much more. It features case studies devoted to the applications of pharmacogenomics, to
Note:
Description based upon print version of record.
,
Front Cover; Genomic Biomarkers for Pharmaceutical Development; Copyright Page; Contents; Preface; About the Editors; List of Contributors; 1 Application of Translational Science to Clinical Development; 1.1 Introduction; 1.2 Two Approaches to Identify Patient Subsets that are Likely to Respond to Individual Therapeutic Interventions; 1.2.1 Prospective Analysis: The Case of Crizotinib in NSCLC; 1.2.1.1 Retrospective Analysis to Identify Responders; 1.2.1.2 Large Molecule Inhibitors of Epidermal Growth Factor Receptor (EGFR); 1.2.1.3 Small Molecule Inhibitors of EGFR: Case of Gefitinib
,
1.2.1.4 Case of Pegylated Interferon (IFN) in Infectious Disease1.3 Use of a Genomic Pharmacodynamics (PD) Marker to Aid in Dose Selection in Clinical Development; 1.4 Safety; 1.4.1 Case Study: Abacavir in HIV; 1.4.2 PPARgamma Agonists in Type II Diabetes; 1.5 Conclusions; References; 2 Personalized Health Care (PHC) in Cancer; 2.1 Introduction; 2.2 Biomarkers; 2.2.1 Pharmacodynamic Biomarkers; 2.2.2 Predictive Biomarkers; 2.2.2.1 Target/Pathway Expression; Estrogen Receptor (ER) and Hormone Therapy in Breast Cancer; Herceptin/Trastuzumab for Breast Cancer
,
PD-1 for Immunotherapy in Multiple Indications2.2.2.2 Target/Pathway Mutation or Genetic Alteration; EGFR MAB Therapy in CRC; EGFR TKI Therapy in NSCLC; BCR/ABL Translocation, ALK Fusions, and PML-RARA Fusion; BRAF Mutation for Vemurafenib; 2.2.2.3 Drug Metabolism; UGT1A and Irinotecan; TPMT and Chemotherapy in ALL; CYP2D6 and Hormone Therapy in Breast Cancer; 2.2.3 Prognostic Biomarkers; 2.2.4 Resistance Biomarkers; 2.2.5 Surrogate Biomarkers; 2.3 Companion Diagnostics; 2.4 Conclusions; References; 3 Personalized Healthcare in Autoimmune Diseases; 3.1 Introduction
,
3.2 Interferon Gamma (IFN-γ) as a Pharmacodynamic (PD) Marker for Ustekinumab (CNTO 1275) in Psoriasis3.3 A Type I Interferon Signature as a PD Marker and Potential Predictive Marker for anti-type I Interferon Therapy in Syst...; 3.4 Biomarker for Anti-CD20 mAb Therapy in Patients with Rheumatoid Arthritis (RA); 3.4.1 Rituximab Depletes Circulating B Cells and Shows Clinical Efficacy in Patients with RA; 3.4.2 IgJ mRNA as a Predictive Marker of Non-response to Rituximab Therapy in Patients with RA
,
3.4.3 RA Patients with High Baseline Type I Interferon Signature are Less Likely to Respond to Anti-CD20 mAb Therapy3.4.4 A Type I Interferon Signature as a Pharmacodynamic Marker of Anti-CD20 mAb Therapy in Patients with RA; 3.5 A Type I INTERFERON Signature as a Predictive Marker of Response to INTERFERON-β Therapy in Patients with Multiple Scle...; Acknowledgments; References; 4 Molecular Heterogeneity, Biomarker Discovery, and Targeted Therapy in Asthma; 4.1 Introduction: Asthma Heterogeneity; 4.2 Molecular Heterogeneity in Asthma; 4.2.1 Gene Expression Studies in the Asthmatic Airway
,
4.2.2 Translation to Non-Invasive Biomarkers
,
English
Additional Edition:
ISBN 0-12-397336-8
Additional Edition:
ISBN 1-299-73888-5
Language:
English
Bookmarklink
